Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company today reported financial results for the three months...
MYL LOSS ALERT: Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline in Class Action Filed by Firm - MYL
17 nov. 2016 11h40 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Mylan Inc., predecessor of Mylan N.V., and/or Mylan N.V....
Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial
07 nov. 2016 16h10 HE
|
Agile Therapeutics, Inc.
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017 Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Mylan N.V. - MYL
02 nov. 2016 16h53 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Mylan N.V. securities and...
Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline
12 juil. 2016 16h12 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new...
Agile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer
06 juil. 2016 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of...